Results 51 to 60 of about 30,845,260 (288)

Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis

Advanced Science, EarlyView.
Researchers developed an engineered probiotic encapsulated in an inulin hydrogel, enabling ultrasound‐triggered intestinal delivery of IL‐22. In MASH model mice, this system remodeled gut microbiota, strengthened the intestinal barrier and reduced portal LPS and hepatic IL‐6.
Chunya Ji, Yan Fang, Shen Zhang, Weichen Xu, Wenyun Guo, Jing Chen, Mingrui Zhu, Congjian Wen, Siming Chen, Yuli Zhu, Huixiong Xu, Haohao Yin   +11 more
wiley   +1 more source

Assessing the Mucosal Inflammatory Endotype of Obesity in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory syndrome of the paranasal sinuses that is defined phenotypically as either with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP). More recently, inflammatory markers have been used to cluster patients into putative endotypes that are presumed to have a common ...
Jeffanie W. Gayoso, Li‐Ching Huang, Quanhu Sheng, Daniel Lofgren, Ping Li, Katherine Cahill, Mason Krysinski, Rakesh K. Chandra, Justin H. Turner, Naweed Chowdhury   +9 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery

Frontiers in Drug Delivery
GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions
R. R. C. New, R. R. C. New, M. Bogus, G. N. Travers, U. Hahn, A. Vaiceliunaite, M. Burnet, J. H. Wang, H. Wen   +8 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives

Kidney Medicine
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based therapies initially developed for the management of type 2 diabetes. In addition to improving glycemic control and promoting weight loss, these agents have demonstrated cardiovascular ...
Mackenzi Meier, Jamessa Cummings, Mohammed Abdelsaid, Jose Feliciano, Jazmin Eusebe, Hanna Stirn, Maha Coucha   +6 more
doaj   +1 more source

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Deepson S Shyangdan, Christine Clar, Pawana Sharma, Royle, Pamela L, Sharma Pawana, Royle Pamela L, Clar, Christine, Clar, C., Waugh, Norman R, Waugh Norman R, Pamela L Royle, Shyangdan Deepson S, Clar Christine, Waugh, Norman, Norman R Waugh, Sharma, Pawana, Shyangdan, D. (Deepson), Shyangdan, Deepson S, Royle, Pamela   +18 more
core   +2 more sources

Enhancing Meat Quality Through Dietary Fiber: Insights Into the Gut Microbiota‐Derived Short‐Chain Fatty Acids‐Muscle Axis

Animal Research and One Health, EarlyView.
Dietary fiber (DF) modulates meat quality through the gut‐muscle axis by reshaping gut microbiota, improving intestinal integrity, reducing inflammation, and regulating muscle metabolism. These mechanisms influence muscle fiber characteristics and post‐mortem biochemistry, thereby enhancing tenderness, juiciness, color, flavor, and nutritional value of
Zeshan Zulfiqar, Muhammad Arslan Asif, Layla Al‐Mitib, Nabeela Ashiq, Haojie Wang, Yalei Cui, Boshuai Liu, Shucheng Huang, Yinghua Shi   +8 more
wiley   +1 more source

Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

Journal of Diabetes Research, 2019
Background. Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs, but there is concern that they may increase the risk of malignant neoplasia. The present meta-analysis examined the safety of GLP-1 receptor agonists with
Yufang Liu, Xiaomei Zhang, Sanbao Chai, Xin Zhao, Linong Ji   +4 more
doaj   +1 more source

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches

Biology, 2020
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted from the gut upon nutrient stimulation and regulate postprandial metabolism.
Geke Aline Boer, Jens Juul Holst
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Emerging role of GLP-1 receptor agonists in the treatment of obesity

, 2010
Lisa M Neff1, Robert F Kushner21Division of Endocrinology, Metabolism, and Molecular Medicine, 2Division of General Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: The prevalence of obesity
Lisa M Neff, Robert F Kushner
core   +1 more source